trial · primary record
Bevacizumab
Solid Tumors
| Phase | Phase 1 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 50 |
| Primary completion | 2018-09-20 |
| Primary endpoint | Determine the toxicity profile of the combination of dasatinib and bevacizumab |
| Registry ID | NCT01445509 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:32:11.698Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT01445509
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Bevacizumab · compound